BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines 2016 Plan — Remaining Scheme Mandate Available for Future Grants (M shares) (M)
HKEX Form FF301 Monthly Returns (06160.HK)
Latest, Sep 2026
114
Period ended Sep 28, 2026
Change on a year earlier
+89.8%
59.9 in Sep 2025
History
63 months
Since Jul 2021
Sources
63
Documents cited below
Monthly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2016 Plan — Remaining Scheme Mandate Available for Future Grants (M shares) (M) | Year on year | Source |
|---|---|---|---|---|
| Sep 2026 | Sep 28, 2026 | 114 | +89.8% | HKEX FF301 (2026-09) ↗ |
| Aug 2026 | Aug 28, 2026 | 114 | +90.9% | HKEX FF301 (2026-08) ↗ |
| Jul 2026 | Jul 28, 2026 | 114 | +89.9% | HKEX FF301 (2026-07) ↗ |
| Jun 2026 | Jun 28, 2026 | 114 | +93.3% | HKEX FF301 (2026-06) ↗ |
| May 2026 | May 28, 2026 | 61.6 | -26.9% | HKEX FF301 (2026-05) ↗ |
| Apr 2026 | Apr 28, 2026 | 61.7 | -28.0% | HKEX FF301 (2026-04) ↗ |
| Mar 2026 | Mar 28, 2026 | 61.4 | -27.4% | HKEX FF301 (2026-03) ↗ |
| Feb 2026 | Feb 28, 2026 | 61.8 | -26.0% | HKEX FF301 (2026-02) ↗ |
| Jan 2026 | Jan 28, 2026 | 61.1 | -25.9% | HKEX FF301 (2026-01) ↗ |
| Dec 2025 | Dec 28, 2025 | 60.6 | -27.0% | HKEX FF301 (2025-12) ↗ |
| Nov 2025 | Nov 28, 2025 | 60.6 | -26.4% | HKEX FF301 (2025-11) ↗ |
| Oct 2025 | Oct 28, 2025 | 60.6 | -27.0% | HKEX FF301 (2025-10) ↗ |
| Sep 2025 | Sep 28, 2025 | 59.9 | -27.2% | HKEX FF301 (2025-09) ↗ |
| Aug 2025 | Aug 28, 2025 | 59.6 | -27.3% | HKEX FF301 (2025-08) ↗ |
| Jul 2025 | Jul 28, 2025 | 59.9 | -27.9% | HKEX FF301 (2025-07) ↗ |
| Jun 2025 | Jun 28, 2025 | 58.8 | -28.3% | HKEX FF301 (2025-06) ↗ |
| May 2025 | May 28, 2025 | 84.3 | +133.0% | HKEX FF301 (2025-05) ↗ |
| Apr 2025 | Apr 28, 2025 | 85.7 | +128.3% | HKEX FF301 (2025-04) ↗ |
| Mar 2025 | Mar 28, 2025 | 84.6 | +129.2% | HKEX FF301 (2025-03) ↗ |
| Feb 2025 | Feb 28, 2025 | 83.5 | +129.5% | HKEX FF301 (2025-02) ↗ |
| Jan 2025 | Jan 28, 2025 | 82.4 | +123.1% | HKEX FF301 (2025-01) ↗ |
| Dec 2024 | Dec 28, 2024 | 83.1 | +121.0% | HKEX FF301 (2024-12) ↗ |
| Nov 2024 | Nov 28, 2024 | 82.4 | +122.8% | HKEX FF301 (2024-11) ↗ |
| Oct 2024 | Oct 28, 2024 | 83.0 | +117.5% | HKEX FF301 (2024-10) ↗ |
| Sep 2024 | Sep 28, 2024 | 82.3 | +119.7% | HKEX FF301 (2024-09) ↗ |
| Aug 2024 | Aug 28, 2024 | 82.0 | +113.2% | HKEX FF301 (2024-08) ↗ |
| Jul 2024 | Jul 28, 2024 | 83.0 | +108.3% | HKEX FF301 (2024-07) ↗ |
| Jun 2024 | Jun 28, 2024 | 82.1 | +111.1% | HKEX FF301 (2024-06) ↗ |
| May 2024 | May 28, 2024 | 36.2 | -50.9% | HKEX FF301 (2024-05) ↗ |
| Apr 2024 | Apr 28, 2024 | 37.6 | -49.9% | HKEX FF301 (2024-04) ↗ |
| Mar 2024 | Mar 28, 2024 | 36.9 | -50.5% | HKEX FF301 (2024-03) ↗ |
| Feb 2024 | Feb 28, 2024 | 36.4 | -51.2% | HKEX FF301 (2024-02) ↗ |
| Jan 2024 | Jan 28, 2024 | 36.9 | -50.8% | HKEX FF301 (2024-01) ↗ |
| Dec 2023 | Dec 28, 2023 | 37.6 | -49.9% | HKEX FF301 (2023-12) ↗ |
| Nov 2023 | Nov 28, 2023 | 37 | -50.2% | HKEX FF301 (2023-11) ↗ |
| Oct 2023 | Oct 28, 2023 | 38.2 | -48.8% | HKEX FF301 (2023-10) ↗ |
| Sep 2023 | Sep 28, 2023 | 37.5 | -49.6% | HKEX FF301 (2023-09) ↗ |
| Aug 2023 | Aug 28, 2023 | 38.4 | -49.0% | HKEX FF301 (2023-08) ↗ |
| Jul 2023 | Jul 28, 2023 | 39.9 | -47.2% | HKEX FF301 (2023-07) ↗ |
| Jun 2023 | Jun 28, 2023 | 38.9 | -47.8% | HKEX FF301 (2023-06) ↗ |
| May 2023 | May 28, 2023 | 73.7 | +59.6% | HKEX FF301 (2023-05) ↗ |
| Apr 2023 | Apr 28, 2023 | 75.0 | +57.9% | HKEX FF301 (2023-04) ↗ |
| Mar 2023 | Mar 28, 2023 | 74.5 | +55.3% | HKEX FF301 (2023-03) ↗ |
| Feb 2023 | Feb 28, 2023 | 74.6 | +53.5% | HKEX FF301 (2023-02) ↗ |
| Jan 2023 | Jan 28, 2023 | 75.0 | +52.0% | HKEX FF301 (2023-01) ↗ |
| Dec 2022 | Dec 28, 2022 | 75.0 | +47.5% | HKEX FF301 (2022-12) ↗ |
| Nov 2022 | Nov 28, 2022 | 74.3 | +45.4% | HKEX FF301 (2022-11) ↗ |
| Oct 2022 | Oct 28, 2022 | 74.5 | +46.3% | HKEX FF301 (2022-10) ↗ |
| Sep 2022 | Sep 28, 2022 | 74.4 | +47.0% | HKEX FF301 (2022-09) ↗ |
| Aug 2022 | Aug 28, 2022 | 75.3 | +49.7% | HKEX FF301 (2022-08) ↗ |
| Jul 2022 | Jul 28, 2022 | 75.6 | +47.9% | HKEX FF301 (2022-07) ↗ |
| Jun 2022 | Jun 28, 2022 | 74.4 | – | HKEX FF301 (2022-06) ↗ |
| May 2022 | May 28, 2022 | 46.2 | – | HKEX FF301 (2022-05) ↗ |
| Apr 2022 | Apr 28, 2022 | 47.5 | – | HKEX FF301 (2022-04) ↗ |
| Mar 2022 | Mar 28, 2022 | 48.0 | – | HKEX FF301 (2022-03) ↗ |
| Feb 2022 | Feb 28, 2022 | 48.6 | – | HKEX FF301 (2022-02) ↗ |
| Jan 2022 | Jan 28, 2022 | 49.3 | – | HKEX FF301 (2022-01) ↗ |
| Dec 2021 | Dec 28, 2021 | 50.9 | – | HKEX FF301 (2021-12) ↗ |
| Nov 2021 | Nov 28, 2021 | 51.1 | – | HKEX FF301 (2021-11) ↗ |
| Oct 2021 | Oct 28, 2021 | 50.9 | – | HKEX FF301 (2021-10) ↗ |
| Sep 2021 | Sep 28, 2021 | 50.6 | – | HKEX FF301 (2021-09) ↗ |
| Aug 2021 | Aug 28, 2021 | 50.3 | – | HKEX FF301 (2021-08) ↗ |
| Jul 2021 | Jul 28, 2021 | 51.1 | – | HKEX FF301 (2021-07) ↗ |
Cite this data
StockData. (2026). BeOne Medicines 2016 Plan — Remaining Scheme Mandate Available for Future Grants (M shares) (M), monthly Jul 2021–Sep 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/hkex_plan_mandate
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.